Foxm1 peptides and vaccines containing the same

An immunology and antigen technology, applied in the field of drugs for the treatment and prevention of tumors, can solve problems such as low objective response rate

Active Publication Date: 2012-04-04
ONCOTHERAPY SCI INC
View PDF17 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, only low objective response rates have been observed so far in these cancer vaccine trials (NPL 11: Belli F et al., J Clin Oncol 2002 Oct 15, 20(20): 4169-80; NPL 12: Coulie PG et al., Immunol Rev 2002Oct, 188:33-42; NPL 13: Rosenberg SA et al., Nat Med 2004Sep, 10(9):909-15)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Foxm1 peptides and vaccines containing the same
  • Foxm1 peptides and vaccines containing the same
  • Foxm1 peptides and vaccines containing the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0288] Materials and methods

[0289] cell line

[0290] The HLA-A*2402 positive B-lymphoblastoid cell line TISI was purchased from IHWG Cell and GeneBank (Seattle, WA). African green monkey kidney cell line COS7 was purchased from ATCC.

[0291] Selection of candidates for FOXM1-derived peptides

[0292] Using the binding prediction software "BIMAS" (www-bimas.cit.nih.gov / molbio / hla_bind) (Parker et al. (J Immunol 1994, 152(1): 163-75), Kuzushima et al. (Blood 2001, 98(6):1872-81)) and "NetMHC3.0" (www.cbs.dtu.dk / services / NetMHC / ) (Buus et al. (Tissue Antigens., 62:378-84, 2003), Nielsen et al. al. (Protein Sci., 12:1007-17, 2003, Bioinformatics, 20(9):1388-97, 2004)) predicts FOXM1-derived 9-mer and 10-mer peptides that bind HLA-A*2402 molecules . The peptides were synthesized by Biosynthesis (Lewisville, Texas) following standard solid phase synthesis and purified by reverse phase high performance liquid chromatography (HPLC). The purity (>90%) and identity of the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides isolated peptides having the amino acid sequence of SEQ ID NO: 34 or fragments thereof, which bind to HLA antigen and induce cytotoxic T lymphocyte (CTL). The present invention further provides peptides which include one, two, or several amino acid insertions, substitution or addition to the aforementioned peptides or fragments, but still have the cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances or compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances or compositions of the present invention may be used for treating cancer or tumor.

Description

technical field [0001] priority [0002] This application claims the benefit of US Provisional Application No. 61 / 153,408, filed February 18, 2009, the entire contents of which are incorporated herein by reference. [0003] The present invention relates to the field of biological sciences, more specifically to the field of cancer treatment. Specifically, the present invention relates to novel peptides that are extremely effective as cancer vaccines, and drugs for treating and preventing tumors. Background technique [0004] It has been demonstrated that CD8-positive CTLs can recognize epitope peptides derived from tumor-associated antigens (TAAs) on major histocompatibility complex (MHC) class I molecules, and then kill tumor cells. Since the discovery of the first example of TAA, the melanoma antigen (MAGE) family, many other TAAs have been discovered by immunological means (NPL 1: Boon T, Int J Cancer 1993 May 8, 54(2): 177 -80; NPL2: Boon T & van der Bruggen P, J Exp ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K31/7088A61K38/00A61P35/00C07K14/47C12N5/0783C12N5/0784C12N5/10
CPCA61K39/0011A61K38/00A61K2039/5158C07K14/4748A61K2039/57A61K31/7088A61P35/00A61P37/04
Inventor 角田卓也大泽龙司吉村祥子渡边朝久
Owner ONCOTHERAPY SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap